Exelixis Financial Ratios
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Exelixis ratio analysis
Exelixis earned a net margin of 33.7% in FY 2025, up from 24.0% a year earlier. Gross margin was 96.4% compared with a median of 96.5% over the prior 9 years. Return on equity reached 36.2%, meaning Exelixis generated 0.36 dollars of profit for every dollar of shareholders' equity.
At the end of FY 2025, EXEL traded at 15.7 times earnings; across the 9 fiscal years shown, its year-end P/E ranged from 8.8 to 62.0, with a median of 25.4. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Exelixis financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 15.68 | 19.30 | 36.91 | 28.64 | 25.39 | 57.34 | 16.68 | 8.80 | 62.04 | — |
| Price / sales | 5.10 | 4.54 | 4.17 | 3.20 | 4.01 | 6.27 | 5.32 | 6.78 | 19.72 | 19.51 |
| Price / book | 5.48 | 4.39 | 3.37 | 2.07 | 2.60 | 3.29 | 3.05 | 4.50 | 31.32 | 41.82 |
| Gross margin | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | 96.3% | 96.6% | 96.9% | 96.7% | 96.6% |
| Operating margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | -14.7% |
| Net margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | -36.7% |
| Free cash flow margin | 37.7% | 31.0% | 16.0% | 20.8% | 24.2% | 18.1% | 53.1% | 44.8% | 31.9% | 106.9% |
| Return on equity (ROE) | 36.2% | 23.2% | 9.2% | 7.3% | 10.5% | 5.9% | 19.0% | 53.6% | 54.1% | -78.6% |
| Return on assets (ROA) | 27.5% | 17.7% | 7.1% | 5.9% | 8.8% | 5.2% | 17.0% | 48.5% | 23.5% | -11.8% |
| Debt / equity | — | — | — | — | — | — | — | — | 0.00 | 2.12 |
| Current ratio | 3.56 | 3.63 | 3.34 | 4.99 | 5.43 | 7.06 | 7.08 | 8.50 | 4.21 | 1.74 |
| Revenue growth | 7.0% | 18.5% | 13.6% | 12.3% | 45.3% | 2.0% | 13.3% | 88.7% | 136.3% | 0.0% |
| EPS growth | 58.0% | 170.8% | 16.1% | -22.2% | 105.7% | -65.7% | -53.8% | 351.0% | — | — |